Skip to content
OpenCapital
Get started

Galectin Therapeutics GALT Q3 2025 earnings

Reported November 14, 2025 · Before market open

Diluted EPS-$0.13Miss by $0.02
EPS estimate-$0.11

Next report

Aug 13, 2026 (In 4 weeks)
EPS estimate-$0.09

Versus estimates

Revenue

Q4 2024$36.0K

Diluted EPS

Q1 2026-$0.08Miss by $0.02Q4 2025-$0.08Beat by $0.02
Q3 2025-$0.13Miss by $0.02
Q2 2025-$0.12Beat by $0.04Q1 2025-$0.15Beat by $0.05Q4 2024-$0.19Miss by $0.03

Ask the moment Galectin Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Galectin Therapeutics report Q3 2025 earnings?
Galectin Therapeutics (GALT) reported Q3 2025 earnings on November 14, 2025 before market open.
What were Galectin Therapeutics's Q3 2025 revenue and EPS?
Galectin Therapeutics reported diluted EPS of $-0.13 for Q3 2025.
Did Galectin Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.11 by $0.02.
How did Galectin Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 27.8% from $-0.18.
Where can I find Galectin Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001140361-25-042118) and the 10-Q periodic report (0001140361-25-042116) directly on SEC EDGAR. The filing index links above go to sec.gov.